New Nominative lists with reimbursable brand-specific devices for vascular surgery introduced in Belgium

03

May 2021

On April 22, 2021, the List of reimbursable implants and invasive medical devices, maintained by the National Institute for Health and Disability Insurance (INAMI), was updated with the corresponding Nominative lists of brand-specific devices. Two new Nominative lists with reimbursable devices used for peripheral vascular interventions were introduced.

Newly-introduced Nominative list 360, “Drug-eluting stent (femoropopliteal arteries),” includes the following devices:

  • 360030000114 Zilver PTX Drug-Eluting Peripheral Stent by Cook;
  • 360030000213 Eluvia - Drug-Eluting Vascular Stent System by Boston Scientific Benelux.

The reimbursement tariff for these devices is €1,485.70.

Newly-introduced Nominative list 361 “Drug-eluting balloon (femoropopliteal arteries)” includes the following devices:

  • 361050000149 IN.PACT Pacific by Medtronic;
  • 361050000248 IN.PACT Admiral by Medtronic;
  • 361050000347 and 361050000446 Stellarex drug-coated balloon by SPECTRANETICS;
  • 361050000545 and 361050000644 Stellarex drug-coated balloon by Medicor;
  • 361050000743 Ranger DCB OTW by Boston Scientific Benelux;
  • 361050000842 Ranger SL DCB OTW by Boston Scientific Benelux;
  • 361050000941 Luminor 18 paclitaxel-eluting PTA balloon by iVascular;
  • 361050001040 Sequent Please OTW by B Braun;
  • 361050001139 Luminor 35 paclitaxel-eluting PTA balloon by iVascular.

The reimbursement tariff for these devices is €1,485.70.

The Nominative lists can be seen here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

11

May 2021

In late April and early May 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, fifteen health apps are now available at the DiGA Directory.

Read more

05

May 2021

Transcatheter aortic valve implantation (TAVI/TAVR) in severe aortic stenosis treatment across all surgical risk groups was being evaluated within the "New Methods" framework since 2019. On April 26, 2021, the Decision Forum for "New Methods" made a positive coverage decision for TAVI/TAVR to treat patients with severe aortic stenosis across all surgical risk groups.

Read more

04

May 2021

In April 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0176 and 0073 with changes to be implemented not later than August 01, 2021. Four new procedure codes related to men's health and breast surgery and one new companion diagnostic code were introduced.

Read more

22

Apr 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2021. Two new EBM codes for IVD tests were introduced, and reimbursement conditions for two IVD tests were amended.

Read more

13

Apr 2021

On March 23, 2021, the Norwegian Directorate of e-Health released an updated version of the National Laboratory code (NLK) system and associated tariffs for state and private laboratories to be implemented not later than May 01, 2021. NLK system is used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) in outpatient settings since 2018.Thirty-four new codes were added in medical biochemistry and medical microbiology areas.

Read more